Knight Jeff E. 4

What Happened
Jeff E. Knight, Chief Operating Officer of Crinetics Pharmaceuticals (CRNX), sold a total of 9,911 shares on March 16, 2026 in two open-market transactions: 5,950 shares at a VWAP of $37.11 for $220,805, and 3,961 shares at a VWAP of $37.77 for $149,607 — total proceeds ≈ $370,412. The sales were made to satisfy tax-withholding obligations arising from vested restricted stock units.

Key Details

• Transaction dates: March 16, 2026 (reported on Form 4 filed March 18, 2026). Filing appears timely (within the required reporting window).
• Lots/prices: 5,950 shares @ VWAP $37.11 (range $36.42–$37.38); 3,961 shares @ VWAP $37.77 (range $37.42–$38.23).
• Total shares sold: 9,911; total proceeds ≈ $370,412.
• Shares owned after transaction: not specified in the provided excerpt of the filing.
• Footnotes: Sales were to cover tax withholding on RSU vestings (grants from 2022–2025) and were effected by a broker under a Rule 10b5‑1 trading plan.
• Transaction code: S = Sale; tax-withholding code/footnote indicated (F1/F2/F3).

Context
These were routine sell-to-cover transactions tied to RSU vesting and executed under a pre-established 10b5‑1 plan — common administrative actions that do not necessarily indicate a change in the insider’s view of the company. For more detail (exact post-transaction holdings or lot-level data), see the full Form 4 filing (Accession 0001628280-26-019503).